alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 327 studies in Cognitive tests and assessment · free to read (page 3 of 14) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of these 327 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

What “Cognitive tests and assessment” covers

Cognitive tests and assessment — Memory and thinking tests, screening tools and rating scales: how well they measure what they claim to.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of neural transmission (Vienna, Austria : 1996) 2016-02-06

The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. 4 key findings →

Design: cohort study Participants: 197 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Molecular neurodegeneration 2017-03-07

We thus examined whether higher blood cholesterol concentrations were associated with faster cognitive decline in a community-based longitudinal study of Chinese elderly. 4 key findings →

Design: longitudinal study Participants: 90 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2011-04-01

Cognitive dysfunction, including dementia and delirium, is prevalent in geriatric emergency department (ED) patients, but often remains undetected. 4 key findings →

Design: cohort study Participants: 163 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2014-08-15

Delirium is a profound neuropsychiatric disturbance precipitated by acute illness. 4 key findings →

Design: longitudinal study Participants: 465 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnestic mild cognitive impairment and early Alzheimer's Disease on optical coherence tomography angiography

✓ Peer-reviewed alzhub usefulness score 61 out of 100. PloS one 2019-04-02

Patients with Alzheimer's Disease (AD) exhibit decreased retinal blood flow and vessel density (VD). 4 key findings →

Design: case-control study Participants: 16 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Validation of neuropsychological tests for the China Health and Retirement Longitudinal Study Harmonized Cognitive Assessment Protocol

✓ Peer-reviewed alzhub usefulness score 61 out of 100. International psychogeriatrics 2019-07-16

We recruited 825 individuals from the CHARLS sample and 766 subjects from hospitals in six provinces and cities in China. 4 key findings →

Design: longitudinal study Participants: 825 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Movement disorders : official journal of the Movement Disorder Society 2014-11-07

Cognitive impairment is one of the earliest, most common, and most disabling non-motor symptoms in Parkinson's disease (PD). 4 key findings →

Design: cohort study Participants: 360 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI)

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Brain imaging and behavior 2012-12-01

We sought to develop and evaluate a composite memory score from the neuropsychological battery used in the Alzheimer's Disease (AD) Neuroimaging Initiative (ADNI). 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

✓ Peer-reviewed alzhub usefulness score 60 out of 100. NeuroImage 2009-01-21

In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of clinical pharmacy and therapeutics 2010-10-01

What is known Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Archives of neurology 2009-05-01

Cerebrospinal fluid (CSF) levels of Abeta peptide 1-42 (Abeta 42), tau, and phosphorylated tau (ptau) are potential biomarkers of Alzheimer disease. 4 key findings →

Design: longitudinal study Participants: 49 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2018-07-28

A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD). 4 key findings →

Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies

✓ Peer-reviewed alzhub usefulness score 59 out of 100. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2012-02-27

The role of atrial fibrillation in cognitive impairment and dementia, independent of stroke, is uncertain. 4 key findings →

Design: post-hoc analysis Participants: 31,506 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2016-04-19

Knight Alzheimer's Disease Research Center (ADRC) at Washington University (WU). 4 key findings →

Design: longitudinal study Participants: 118 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events